CO6150192A2 - Anticuerpos monoclonales anti-il-6 y usos de los mismos - Google Patents
Anticuerpos monoclonales anti-il-6 y usos de los mismosInfo
- Publication number
- CO6150192A2 CO6150192A2 CO09007783A CO09007783A CO6150192A2 CO 6150192 A2 CO6150192 A2 CO 6150192A2 CO 09007783 A CO09007783 A CO 09007783A CO 09007783 A CO09007783 A CO 09007783A CO 6150192 A2 CO6150192 A2 CO 6150192A2
- Authority
- CO
- Colombia
- Prior art keywords
- seq
- amino acid
- acid sequence
- group
- sequence selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
1.- Un anticuerpo monoclonal aislado, el cual comprende: (a) una región variable de cadena pesada (VH) que comprende: (i) una VH-CDR1 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID N0:54, SEQ ID NO:55, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 51 a 55 excepto por 1 a 5 sustituciones de aminoácidos; (ii) una VH-CDR2 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:56, SEQ ID NO:57, SEQ ID N0:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID N0:61 SEQ ID NO:97, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 56 a 61 ó 97 excepto por 1 a 5 sustituciones de aminoácidos; (iii) una VH-CDR3 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO;71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:98, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 62 a 73 ó 98 excepto por 1 a 5 sustituciones de aminoácidos; y (b) una región variable de cadena ligera (VL) que comprende:(i) una VL-CDR1 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO: 79, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 74 a 79 excepto por 1 a 5 sustituciones de aminoácidos; (ii) una VL-CDR2 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, y una secuencia de aminoácidos que es idéntica a cualquiera de las SEQ ID NOs: 80 a 85 excepto por 1 a 5 sustituciones de aminoácidos; (iii) una VL-CDR3 que comprende una secuencia de aminoácidos seleccionada a partir del grupo que consiste en las: SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83510706P | 2006-08-03 | 2006-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6150192A2 true CO6150192A2 (es) | 2010-04-20 |
Family
ID=39033490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09007783A CO6150192A2 (es) | 2006-08-03 | 2009-01-28 | Anticuerpos monoclonales anti-il-6 y usos de los mismos |
Country Status (17)
Country | Link |
---|---|
US (1) | US7919095B2 (es) |
EP (1) | EP2064241B1 (es) |
JP (1) | JP2009545319A (es) |
KR (1) | KR101479537B1 (es) |
CN (1) | CN101563365B (es) |
AU (1) | AU2007282023B2 (es) |
BR (1) | BRPI0715115A2 (es) |
CA (1) | CA2657763C (es) |
CO (1) | CO6150192A2 (es) |
CR (1) | CR10563A (es) |
EA (1) | EA200900037A1 (es) |
IL (1) | IL196550A0 (es) |
MA (1) | MA30653B1 (es) |
MX (1) | MX2009001110A (es) |
NO (1) | NO20090224L (es) |
WO (1) | WO2008019061A2 (es) |
ZA (1) | ZA200900514B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
EP2164514B1 (en) | 2007-05-21 | 2016-12-14 | AlderBio Holdings LLC | Antibodies to il-6 and use thereof |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
WO2009140348A2 (en) | 2008-05-13 | 2009-11-19 | Novimmune Sa | Anti-il-6/il-6r antibodies and methods of use thereof |
US8188235B2 (en) * | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
JP2012503490A (ja) * | 2008-09-26 | 2012-02-09 | ワイス・エルエルシー | 単鎖抗体ライブラリー設計 |
CA2742786A1 (en) * | 2008-11-13 | 2010-05-20 | Femta Pharmaceuticals, Inc. | Humanized anti-il-6 antibodies |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
EP2361095B1 (en) | 2008-11-25 | 2017-12-20 | AlderBio Holdings LLC | Antagonists of il-6 to raise albumin and/or lower crp |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
CN102740888B (zh) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
CN102971012B (zh) | 2010-03-12 | 2016-05-04 | 伊缪诺金公司 | Cd37结合分子及其免疫缀合物 |
CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
WO2012098238A1 (en) | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
JP6018622B2 (ja) * | 2011-04-01 | 2016-11-02 | イミュノジェン, インコーポレイテッド | Cd37結合性分子及びその免疫複合体 |
WO2013175276A1 (en) * | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
CA2889181C (en) * | 2012-10-22 | 2021-12-07 | Fountain Biopharma Inc. | Antibodies to interleukin-6 and uses thereof |
SG11201502876RA (en) * | 2012-11-08 | 2015-06-29 | Eleven Biotherapeutics Inc | Il-6 antagonists and uses thereof |
MA44391A (fr) | 2015-06-08 | 2019-01-23 | Debiopharm Int Sa | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 |
ES2877708T3 (es) | 2015-07-31 | 2021-11-17 | Medimmune Ltd | Antagonistas de IL-6 para su uso en el tratamiento de trastornos mediados por hepcidina |
JP6890581B2 (ja) | 2015-08-28 | 2021-06-18 | デビオファーム インターナショナル, エス. アー. | Cd37の検出のための抗体およびアッセイ |
EA201891732A1 (ru) * | 2016-02-02 | 2019-02-28 | Кадмон Корпорейшн, Ллк | Биспецифичные связывающие белки для pd-l1 и kdr |
JP7311113B2 (ja) * | 2016-05-05 | 2023-07-19 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Il-6及びcd126を標的とするdnaモノクローナル抗体 |
JP2020510608A (ja) | 2016-11-02 | 2020-04-09 | デビオファーム インターナショナル, エス. アー. | 抗cd37イムノコンジュゲート療法を改善するための方法 |
SG10201912128SA (en) | 2017-02-01 | 2020-02-27 | Univ Yale | Treatment of diuretic resistance |
MA51584A (fr) | 2018-01-05 | 2020-11-11 | Corvidia Therapeutics Inc | Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression |
CN109517064B (zh) * | 2018-10-10 | 2020-05-08 | 北京汇智和源生物技术有限公司 | 白介素-6的人源化单克隆抗体、其编码基因及应用 |
WO2020257586A2 (en) | 2019-06-20 | 2020-12-24 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
CN112279913B (zh) * | 2020-10-30 | 2022-05-03 | 上海百英生物科技有限公司 | 一种抗人il-6单克隆抗体及应用 |
EP4252243A2 (en) | 2020-11-30 | 2023-10-04 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
CN113980129B (zh) * | 2021-01-15 | 2023-07-28 | 东大生物技术(苏州)有限公司 | 一组il-11单克隆抗体及其医药用途 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2598666B2 (ja) * | 1987-10-19 | 1997-04-09 | 忠三 岸本 | 抗ヒトbcdfモノクローナル抗体 |
IL88375A (en) | 1988-11-14 | 1995-07-31 | Yeda Res & Dev | Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
JPH03139292A (ja) * | 1989-05-22 | 1991-06-13 | Toray Ind Inc | ヒトインタ―ロイキン―6に対するモノクロ―ナル抗体 |
EP0399429A1 (en) * | 1989-05-22 | 1990-11-28 | Toray Industries, Inc. | Anti-human interleukin-6 monoclonal antibody |
JP2881311B2 (ja) * | 1989-07-28 | 1999-04-12 | 味の素株式会社 | 抗ヒトbcdfモノクローナル抗体及びそれを用いたヒトbcdfの定量法 |
DE3939706C1 (es) * | 1989-12-01 | 1991-03-21 | Centre Regional De Transfusion Sanguine, Besancon, Fr | |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
WO1994028159A1 (fr) | 1993-05-31 | 1994-12-08 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstruit contre l'interleukine-6 humaine |
JP3614183B2 (ja) * | 1993-05-31 | 2005-01-26 | 中外製薬株式会社 | ヒトインターロイキン−6に対する再構成ヒト抗体 |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
WO1995033483A1 (fr) | 1994-06-07 | 1995-12-14 | Toray Industries, Inc. | Agent preventif et curatif contre les maladies provoquees par la formation de fibrinoides ou de thrombus dans les poumons et modele animal pour ces maladies |
RU2147443C1 (ru) | 1994-10-07 | 2000-04-20 | Чугаи Сейяку Кабусики Кайся | Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента |
ES2170815T5 (es) | 1994-12-29 | 2012-11-14 | Chugai Seiyaku Kabushiki Kaisha | Uso de un anticuerpo PM-1 o de un anticuerpo MH166 para potenciar el efecto antitumoral de cisplatino o carboplatino |
GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
DK2011514T3 (da) | 1997-03-21 | 2012-03-26 | Chugai Pharmaceutical Co Ltd | Forebyggende eller terapeutisk middel til sensibiliserede-T-celle-medierede sygdomme omfattende IL-6-antagonist som en aktiv bestanddel |
WO1999047170A1 (fr) | 1998-03-17 | 1999-09-23 | Chugai Seiyaku Kabushiki Kaisha | Agents prophylactiques ou therapeutiques pour affections intestinales inflammatoires renfermant, comme ingredient actif, des antagonistes de il-6 |
US7494652B1 (en) | 1998-06-10 | 2009-02-24 | Promega Corporation | Treatment of sepsis |
ES2276525T3 (es) | 1998-08-24 | 2007-06-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo. |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
JP2003525862A (ja) | 1999-01-27 | 2003-09-02 | ザ ユニヴァーシティー オブ サウス フロリダ | ヒト癌の治療のためのstat3シグナル伝達の阻害 |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
ATE457177T1 (de) | 2000-05-03 | 2010-02-15 | Medimmune Llc | Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe |
US7320792B2 (en) | 2000-10-25 | 2008-01-22 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist |
JP4889187B2 (ja) | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤 |
US20050196755A1 (en) * | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
JP2004536786A (ja) | 2001-03-02 | 2004-12-09 | メディミューン,インコーポレイテッド | インテグリンαvβ3拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法 |
AU2002250236A1 (en) | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
PT1562968E (pt) * | 2001-11-14 | 2013-10-23 | Janssen Biotech Inc | Anticorpos anti-il-6, composições, métodos e utilizações |
JP4323317B2 (ja) | 2001-12-21 | 2009-09-02 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | 可変領域配列のクローニング方法 |
US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
JP4463104B2 (ja) * | 2002-08-30 | 2010-05-12 | 財団法人化学及血清療法研究所 | ヒト抗ヒトインターロイキン−6抗体及び該抗体フラグメント |
EP1572103A4 (en) | 2002-11-15 | 2008-02-13 | Centocor Inc | ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS |
EP1594897A4 (en) | 2003-02-04 | 2006-11-08 | Centocor Inc | USE OF IL-6 ANTAGONISTS IN COMBINATION WITH STEROIDS FOR INCREASED APOPTOSIS |
EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
PL378199A1 (pl) | 2003-02-24 | 2006-03-06 | Chugai Seiyaku Kabushiki Kaisha | Środek terapeutyczny do stosowania w urazach rdzenia kręgowego, zawierający antagonistę interleukiny-6 |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
JP2007526022A (ja) | 2003-10-24 | 2007-09-13 | メドトロニック・インコーポレーテッド | 炎症誘発性媒介物質の産生を減弱することによって神経性障害を処置する技法 |
US20050100550A1 (en) | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
WO2005080429A2 (en) | 2004-02-11 | 2005-09-01 | Warner-Lambert Company Llc | Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies |
CA2591587A1 (en) | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
WO2006105665A1 (en) | 2005-04-06 | 2006-10-12 | Bioartificial Gel Technologies Inc. | Hydrogel composition for modulation of topical inflammatory response |
EP1712241A1 (en) | 2005-04-15 | 2006-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
EP1888629B1 (en) | 2005-05-10 | 2013-04-24 | Neoloch Aps | Neuritogenic peptides |
-
2007
- 2007-08-03 AU AU2007282023A patent/AU2007282023B2/en not_active Ceased
- 2007-08-03 BR BRPI0715115-2A patent/BRPI0715115A2/pt not_active Application Discontinuation
- 2007-08-03 JP JP2009522880A patent/JP2009545319A/ja active Pending
- 2007-08-03 EP EP07811042.6A patent/EP2064241B1/en active Active
- 2007-08-03 CA CA2657763A patent/CA2657763C/en not_active Expired - Fee Related
- 2007-08-03 CN CN2007800289537A patent/CN101563365B/zh not_active Expired - Fee Related
- 2007-08-03 MX MX2009001110A patent/MX2009001110A/es not_active Application Discontinuation
- 2007-08-03 EA EA200900037A patent/EA200900037A1/ru unknown
- 2007-08-03 WO PCT/US2007/017337 patent/WO2008019061A2/en active Application Filing
- 2007-08-03 US US11/882,751 patent/US7919095B2/en not_active Expired - Fee Related
- 2007-08-03 KR KR20097003512A patent/KR101479537B1/ko not_active IP Right Cessation
-
2009
- 2009-01-15 NO NO20090224A patent/NO20090224L/no not_active Application Discontinuation
- 2009-01-15 IL IL196550A patent/IL196550A0/en unknown
- 2009-01-15 CR CR10563A patent/CR10563A/es unknown
- 2009-01-22 ZA ZA200900514A patent/ZA200900514B/xx unknown
- 2009-01-28 CO CO09007783A patent/CO6150192A2/es unknown
- 2009-02-17 MA MA31649A patent/MA30653B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CR10563A (es) | 2009-04-14 |
EP2064241A2 (en) | 2009-06-03 |
WO2008019061A2 (en) | 2008-02-14 |
EA200900037A1 (ru) | 2009-10-30 |
CA2657763A1 (en) | 2008-02-14 |
MX2009001110A (es) | 2009-05-11 |
US7919095B2 (en) | 2011-04-05 |
AU2007282023A1 (en) | 2008-02-14 |
ZA200900514B (en) | 2010-04-28 |
AU2007282023B2 (en) | 2012-09-13 |
CN101563365B (zh) | 2012-10-31 |
KR101479537B1 (ko) | 2015-01-07 |
NO20090224L (no) | 2009-03-31 |
BRPI0715115A2 (pt) | 2013-06-04 |
CN101563365A (zh) | 2009-10-21 |
WO2008019061A3 (en) | 2008-10-09 |
US20080075726A1 (en) | 2008-03-27 |
EP2064241B1 (en) | 2015-10-07 |
IL196550A0 (en) | 2011-08-01 |
KR20090039801A (ko) | 2009-04-22 |
MA30653B1 (fr) | 2009-08-03 |
CA2657763C (en) | 2016-05-31 |
JP2009545319A (ja) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6150192A2 (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
RS52713B (en) | MONGLONAL ANTIBODIES BINDING HGM-CSF AND MEDICAL COMPOSITIONS CONTAINING THE SAME | |
AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
AR073232A1 (es) | Anticuerpos anti-il-17a/f biespecificos y con reactividad cruzada | |
AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
PE20121361A1 (es) | Antagonistas de pcsk9 | |
PE20141659A1 (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc | |
NZ603529A (en) | Antibodies to human gdf8 | |
PE20141162A1 (es) | Anticuerpos anti-il-23 | |
NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
CO6190543A2 (es) | Anticuerpos anti-factor d humanizados | |
PE20081478A1 (es) | Anticuerpos cd44 | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
CO6251325A2 (es) | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) | |
CO6362024A2 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4 humano | |
PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
PE20061324A1 (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
CO6331299A2 (es) | Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina | |
PE20140825A1 (es) | Anticuerpos contra il-6 y sus usos |